Clinical Trial Update: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. [Phase 2]

View source ↗

Summary

Phase II trial evaluating CHOP-21 with Obinutuzumab and Ibrutinib in untreated young high‑risk diffuse large B-cell lymphoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Lymphoma, B-Cell | Phase 2 | Status: TERMINATED